Cytometix, Inc.

Other

Lane Brostrom

John Russell Falck

David R Harder

Henry Bordas-Murphy

James B Antczak

John R Falck

Systems, compositions, and methods are disclosed for developing and delivering therapeutically effective 14,15-epoxyeicosatrienoic acid (14,15-EET) analogs, for example for pain management or treatment. Of particular interest are intermediate salts.

Methods of manufacturing 14,15-epoxyeicosatrienoic acid analogs and improved therapeutic delivery of same

The present invention provides a system enabling the oral delivery of therapeutics derived from polyunsaturated fatty acids (PUFAs), their metabolites and derivatives, including, eicosanoids, prostaglandins, prostacyclins, leukotrienes, resolvins, endocannabinoids, thromboxanes, epoxyeicosa-trienoic acids (EETs), hydroxyeicostetraenoic acids (HETEs), and CMX-020. The delivery system includes a vehicle comprising a purified docosahexaenoic acid (DHA) in triglyceride or ester form; a purified eicosapentaenoic acid (EPA) in triglyceride or ester form; a combination of DHA, EPA in either triglyceride or ester forms; or a modified DHA, EPA, or omega-3 fatty acid analog; and optionally, an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH/tonicity adjustment agent.

Compositions and methods for delivery of polyunsaturated fatty acid derivatives and analogs

The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments.

Arachidonic acid analogs and methods for analgesic treatment using same

Methods and uses are described for treating or preventing diseases of humans or non-human animals by reducing the amount of active leukotriene B(LTB) in those in need of such treatment using LTBhydroxylases. In certain embodiments, LTBhydroxylase is administered in combination with nicotinamide adenine dinucleotide phosphate and/or an NADPH-cytochrome P-450 reductase. The invention is particularly useful for treating or preventing respiratory diseases that are caused or exacerbated by inflammation.

Growing community of inventors

Bayside, WI, United States of America

Lane Brostrom